Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-09 01:47:48 UTC - HELPFUL

Rated by Participant: 3765CA200B3D098D1F594F1DD96A1CB4D25146094EFEADA49D3A9E63DA23296D
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 3765CA200B3D098D1F594F1DD96A1CB4D25146094EFEADA49D3A9E63DA23296D
createdAtMillis - 1688867268006
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 1
helpfulEmpathetic - 0
helpfulGoodSources - 1
helpfulUniqueContext - 0
helpfulAddressesClaim - 1
helpfulImportantContext - 1
helpfulUnbiasedLanguage - 1
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 0
ratingsId - 16778032330775224323765CA200B3D098D1F594F1DD96A1CB4D25146094EFEADA49D3A9E63DA23296D